Form 4: Cognition Therapeutics CFO Realizes Performance Stock Units, Adjusts Holdings for Tax
Insider Transaction Report
Cognition Therapeutics' Chief Financial Officer, John Brendan Doyle, acquired 30,000 shares through performance stock unit vesting and disposed of 9,360 shares for tax obligations.
Summary
- John Brendan Doyle, Chief Financial Officer of Cognition Therapeutics Inc. (CGTX), reported changes in his beneficial ownership of common stock.
- On July 29, 2025, Mr. Doyle acquired 30,000 shares of common stock at a price of $0.00 per share.
- These shares were earned upon the vesting of performance stock units (PSUs) granted to him on February 14, 2024, with 50% of the total PSUs vesting on this date.
- Concurrently, Mr. Doyle disposed of 9,360 shares of common stock at a price of $0.6702 per share.
- This disposition represents shares withheld by Cognition Therapeutics to cover tax withholding obligations associated with the PSU vesting.
- Following these transactions, Mr. Doyle's direct beneficial ownership of common stock stands at 425,350 shares.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. The vesting of performance stock units indicates the achievement of pre-defined goals, which is a positive for the executive and implies positive performance for the company. The disposition for tax purposes is a standard, neutral event.
Positives
- The vesting of 30,000 performance stock units indicates the achievement of certain performance goals by the reporting person, which is a positive sign for executive performance and potentially company milestones.
Negatives
- A portion of the vested shares (9,360 shares) was disposed of to cover tax withholding obligations, which is a standard procedure but reduces the net shares received by the executive.
Industry Context
This filing is a routine insider transaction report (Form 4) detailing changes in beneficial ownership for a company executive. Such filings are common across all industries and reflect compensation events rather than broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding executive compensation and changes in insider ownership, which can be a factor in investment decisions. The increase in direct ownership (net of tax withholding) aligns executive interests with shareholders.
- Employees: This reflects a standard form of executive compensation, which may influence broader compensation strategies within the company.
Key Dates
| Date | Description |
|---|---|
| 02/14/2024 | Date performance stock units (PSUs) were granted to the Reporting Person. |
| 07/29/2025 | Date of earliest transaction, when 50% of the PSUs vested and shares were acquired, and shares were disposed for tax withholding. |
| 07/31/2025 | Date the Form 4 was signed and filed. |
Keywords
Cognition Therapeutics, CGTX, John Brendan Doyle, Chief Financial Officer, CFO, SEC Form 4, Insider Transaction, Performance Stock Units, PSU, Stock Vesting, Equity Compensation, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.